Endocrine Abstracts

Osteoporosis is a chronic condition requiring long-term treatment; sequential treatment regimens with different agents represents an option aimed to increase bone mineral density (BMD) and then to maintain it. The loss of BMD occurring after withdrawal of teriparatide (TPT) can be prevented by bisphosphonates (BPs). Among BPs, data about the efficacy of zoledronic acid (ZOL) after TPT treatment are scanty. Here, we contribute to this topic providing data derived from the real-...

Osteoporosis management increased determination of serum calcium (Ca) levels, and detection of hypercalcemia in the set of out patients. Serum phosphate (P) levels are less frequently measured in osteometabolic patients. Primary hyperparathyroidism (PHPT) is the most common cause of hypophosphatemia. However, hypophosphatemia receives poor attention during the PHPT diagnostic work up, and also data in literature are scanty. We retrospectively reviewed the clinical records from...

Chronic hypophosphatemia (HP) can be observed among patients (pts) evaluated and treated for osteoporosis, but its prevalence and management are poorly defined. In this study we analyze prevalence, clinical features and diagnostic workup for chronic HP among pts attending a third-level osteoporosis office. Chronic HP was defined as serum phosphate levels persistently < 2.7 mg/dl over a period ≥ 6 months. Tubular reabsorption of phosphate (TRP) was measured and, in pr...

Hypercalciuria may represent a challenge during the workup for osteoporosis management. The present study aimed: 1) to describe the phenotype associated with hypercalciuria in vitamin D-repleted (serum 25OHD > 20 ng/ml) osteopenic/osteoporotic patients, focusing on kidney, bone and mineral metabolic features; 2) to analyze the effects of thiazides and anti-resorptive drugs on urine calcium excretion (UCa) and mineral metabolism markers. Seventy patients (67 postmenopausal ...

Background: Hypophosphatasia is a rare genetic disease with low serum alkaline phosphatase (ALP) activity and hypophosphatasemia. It is caused by loss-of-function mutations and deletions of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) gene; it has a wide range of severity in its phenotype, from death in utero to asymptomatic disease accidentally diagnosed in adult life. Furthermore, some diseases and drugs may induce hypophosphatasemia. Thus, the ...

Current clinical presentation of PHPT is mild disease with an increased risk of fragility fractures. PHPT predominantly occurs in postmenopausal women, who have an increased risk of osteoporosis and fractures due to ageing and loss of estrogen.Aims: To explore skeletal phenotypes in postmenopausal women affected by PHPT with a wide clinical and biochemical spectrum of disease.Patients: Postmenopausal (at least 5 years from last men...